Clinical Trial

Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This trial is designed to evaluate the safety and efficacy of anti-IGF-1R mAb in combination with anti-PD-1 mAb in patients with mCRPC.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-03-07; most recent amendment 2026-07-22.
Status change: Recruiting → Active, Not Recruiting 2025-11-26
Status change: Not Yet Recruiting → Recruiting 2025-04-08
Trial Details
NCT Number NCT06866548
Lead Sponsor Shanghai Changzheng Hospital
Conditions mCRPC
Enrollment 7 participants
Start Date 2025-03-10
Primary Completion 2025-11-11 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-23